Key result
Metastatic CNS involvement in pediatric extracranial Ewing sarcoma was associated with a poor prognosis, with a median event-free survival of 1.9 months and overall survival of 4.6 months.
Why the study?
What is the clinical course and survival of pediatric patients with extracranial Ewing sarcoma who develop CNS metastases?
Case Report (n=6)
No
What is the clinical course and survival of pediatric patients with extracranial Ewing sarcoma who develop CNS metastases?
Answers are grounded in this paper and cite their sources.
Pediatric patients with extracranial Ewing sarcoma who develop CNS metastases have a very poor prognosis, with median overall survival of 4.6 months after CNS disease detection.
Metastatic central nervous system (CNS) involvement is rare in pediatric primary extracranial Ewing sarcoma (ES). We describe the incidence and course of six patients with extracranial ES who developed metastatic CNS lesions treated at a single institution. Median time to CNS disease detection was 16.3 months (10.0-28.3 months). Event free and overall survival after CNS disease detection were 1.9 months (0.4-10.3 months) and 4.6 months (1.1-50.9 months), respectively. One patient was alive at the time of analysis. Clinical status and ability to obtain disease control should be considered when making decisions regarding aggressive interventions in these patients with poor prognosis.
No takes yet. Share an insight, caveat, or question.
Slatnick et al. (2023) conducted a case report in Pediatric primary extracranial Ewing sarcoma with metastatic CNS lesions (n=6). Metastatic CNS involvement was evaluated on Event free and overall survival after CNS disease detection. Metastatic CNS involvement in pediatric extracranial Ewing sarcoma was associated with a poor prognosis, with a median event-free survival of 1.9 months and overall survival of 4.6 months.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: